Abstract
The development of deep learning (DL) models to predict the consensus molecular subtypes (CMS) from histopathology images (imCMS) is a promising and cost-effective strategy to support patient stratification. Here, we investigate whether imCMS calls generated from whole slide histopathology images (WSIs) of rectal cancer (RC) pre-treatment biopsies are associated with pathological complete response (pCR) to neoadjuvant long course chemoradiotherapy (LCRT) with single agent fluoropyrimidine.
DL models were trained to classify WSIs of colorectal cancers stained with hematoxylin and eosin into one of the four CMS classes using a multi-centric dataset of resection and biopsy specimens (n=1057 WSIs) with paired transcriptional data. Classifiers were tested on a held out RC biopsy cohort (ARISTOTLE) and correlated with pCR to LCRT in an independent dataset merging two RC cohorts (ARISTOTLE, n=114 and SALZBURG, n=55 patients).
DL models predicted CMS with high classification performance in multiple comparative analyses. In the independent cohorts (ARISTOTLE, SALZBURG), cases with WSIs classified as imCMS1 had a significantly higher likelihood of achieving pCR (OR=2.69, 95%CI 1.01-7.17, p=0.048). Conversely, imCMS4 was associated with lack of pCR (OR=0.25, 95%CI 0.07-0.88, p=0.031). Classification maps demonstrated pathologist-interpretable associations with high stromal content in imCMS4 cases, associated with poor outcome. No significant association was found in imCMS2 or imCMS3.
imCMS classification of pre-treatment biopsies is a fast and inexpensive solution to identify patient groups that could benefit from neoadjuvant LCRT. The significant associations between imCMS1/imCMS4 with pCR suggest the existence of predictive morphological features that could enhance standard pathological assessment.
Competing Interest Statement
VHK: invited speaker for Sharing Progress in Cancer Care (SPCC) and Indica Labs; advisory board of Takeda; sponsored research agreements with Roche and IAG all unrelated to the current study; participant of a patent application on the assessment of cancer immunotherapy biomarkers by digital pathology; a patent application on multimodal deep learning for the prediction of recurrence risk in cancer patients, and a patent application on predicting the efficacy of cancer treatment using deep learning. JR and KS: co-founders of the Oxford University spinout company Ground Truth Labs (GTL); GTL uses computational pathology to provide biopharma services. TM: consultant for GTL. FH: honoraria from Pierre Fabre, Amgen, Servier, Daiichi Sankyo, BMS, Merck, Sanofi; travel support from Servier, BMS, Roche, Merck, Pharmamar, Pfizer, Pierre Fabre, Sanofi, Daiichi Sankyo, Gilead; scientific advisory role for Servier, Daiichi Sankyo, BMS; holds stock options in Guardant Health. DN: consultant for Boerhinger Ingelheim, Lilly. All other authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
Funding Statement
The S:CORT consortium is a Medical Research Council stratified medicine consortium jointly funded by the MRC and CRUK (MR/M016587/1). The ARISTOTLE trial was funded by Cancer Research UK (CRUK/08/032). This work was supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre. This work was supported by the Research Fund of the Paracelsus Medical University Salzburg, Austria (PMU-FFF R-17/03/090-HUW). Computation used the CTP Lab core resources at the University of Zurich and at the Oxford Biomedical Research Computing (BMRC) facility, a joint development between the Wellcome Centre for Human Genetics and the Big Data Institute supported by Health Data Research UK and the NIHR Oxford Biomedical Research Centre. RW is supported through the EPSRC Center for Doctoral Training in Health Data Science (EP/S02428X/1), Oxford CRUK Cancer Centre. JR is supported through the NIHR Oxford Biomedical Research Centre, the Oxford CRUK Cancer Center, and holds an adjunct appointment at the Ludwig Institute of Cancer Research at the University of Oxford. TM gratefully acknowledges funding by the Medical Research Council and Cancer Research UK. VHK gratefully acknowledges funding by the Swiss National Science Foundation (P2SKP3_168322/1 and P2SKP3_168322/2), and the Promedica Foundation (F-87701-41-01).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All samples in the S:CORT cohorts were obtained following individual informed consent and ethical approval by the National Research Ethics Service in the United Kingdom (ref 15/EE/0241; IRAS reference 169363). The SALZBURG cohort was reviewed by the ethical board of the provincial government of Salzburg, Austria (415-E/2343/5-2018), although under Austrian law informed consent is not needed for research use and is therefore not available for all cases.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Correction of misreported numbers in the abstract, Figure 1 and Figure S1; Updated Figure 4 and caption for improved clarity; Additional content in p.4-5,8-12,22-23 for improved clarity; Rearranged section ordering for improved clarity; Details added to the data availability statement; Updated competing interests statement.
DATA AVAILABILITY STATEMENT
The datasets generated during and/or analysed during the current study are available from the corresponding authors upon reasonable request in accordance with the S:CORT data access policy. The TCGA datasets and images analysed in this study are openly and publicly available at: https://portal.gdc.cancer.gov/.
